150 related articles for article (PubMed ID: 29567811)
1. Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.
Ward E; Varešlija D; Charmsaz S; Fagan A; Browne AL; Cosgrove N; Cocchiglia S; Purcell SP; Hudson L; Das S; O'Connor D; O'Halloran PJ; Sims AH; Hill AD; Young LS
Clin Cancer Res; 2018 Aug; 24(15):3692-3703. PubMed ID: 29567811
[No Abstract] [Full Text] [Related]
2. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
3. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
4. ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
Si X; Liu Y; Lv J; Ding H; Zhang XA; Shao L; Yang N; Cheng H; Sun L; Zhu D; Yang Y; Li A; Han X; Sun Y
Oncotarget; 2016 Apr; 7(15):20966-80. PubMed ID: 26980709
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Stone A; Valdés-Mora F; Gee JM; Farrow L; McClelland RA; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Nicholson RI
PLoS One; 2012; 7(7):e40466. PubMed ID: 22808167
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.
Pathiraja TN; Nayak SR; Xi Y; Jiang S; Garee JP; Edwards DP; Lee AV; Chen J; Shea MJ; Santen RJ; Gannon F; Kangaspeska S; Jelinek J; Issa JP; Richer JK; Elias A; McIlroy M; Young LS; Davidson NE; Schiff R; Li W; Oesterreich S
Sci Transl Med; 2014 Mar; 6(229):229ra41. PubMed ID: 24670685
[TBL] [Abstract][Full Text] [Related]
7. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
[TBL] [Abstract][Full Text] [Related]
8. PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Truong TH; Benner EA; Hagen KM; Temiz NA; Kerkvliet CP; Wang Y; Cortes-Sanchez E; Yang CH; Trousdell MC; Pengo T; Guillen KP; Welm BE; Dos Santos CO; Telang S; Lange CA; Ostrander JH
Oncogene; 2021 Jun; 40(25):4384-4397. PubMed ID: 34103681
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.
Anurag M; Punturi N; Hoog J; Bainbridge MN; Ellis MJ; Haricharan S
Clin Cancer Res; 2018 Oct; 24(19):4887-4899. PubMed ID: 29793947
[No Abstract] [Full Text] [Related]
10. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
11. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Xiao T; Li W; Wang X; Xu H; Yang J; Wu Q; Huang Y; Geradts J; Jiang P; Fei T; Chi D; Zang C; Liao Q; Rennhack J; Andrechek E; Li N; Detre S; Dowsett M; Jeselsohn RM; Liu XS; Brown M
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7869-7878. PubMed ID: 29987050
[TBL] [Abstract][Full Text] [Related]
13. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
14. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JM; Nicholson RI; Print CG; Clark SJ; Musgrove EA
Mol Cancer Ther; 2013 Sep; 12(9):1874-85. PubMed ID: 23861345
[TBL] [Abstract][Full Text] [Related]
15. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
17. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.
Chiu JH; Wen CS; Wang JY; Hsu CY; Tsai YF; Hung SC; Tseng LM; Shyr YM
J Transl Med; 2017 May; 15(1):97. PubMed ID: 28472954
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
19. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
[TBL] [Abstract][Full Text] [Related]
20. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
